Menopause & Perimenopause Support

HPG Axis & Hormonal Signalling

Kisspeptin is the primary compound investigated for direct HPG axis modulation in the menopause context. As the upstream driver of GnRH pulsatility, it sits at a physiologically significant node: disruption of KNDy neuron signalling during perimenopause is implicated in the neurological origin of vasomotor symptoms. Research has investigated whether exogenous Kisspeptin administration or neurokinin B receptor antagonism can modulate this pathway. Gonadorelin, a GnRH analogue, can stimulate pulsatile LH and FSH release and has been studied for preserving pituitary responsiveness during hormonal transitions.

GH Axis, Body Composition & Bone Density

GH peptides for women over 40 represent a category of research interest driven by the convergence of reproductive hormonal decline and age-related GH axis blunting. Sermorelin has been investigated in aging adult cohorts for its capacity to restore more youthful GH pulsatility without directly administering exogenous GH. Ipamorelin's selectivity profile, stimulating GH secretion without elevating cortisol or prolactin, has made it a compound of interest for body composition and bone mineral density research in contexts where adverse endocrine effects are a concern. CJC-1295 (with DAC) extends the effect of each GHRH pulse, sustaining IGF-1 elevation and amplifying the anabolic environment over longer intervals than short-acting analogues.

Metabolic Health & Weight

Perimenopause menopause peptide research in the metabolic domain encompasses both receptor-level interventions and mitochondrial targets. Semaglutide and Tirzepatide are the most clinically validated compounds for weight management and glycaemic control, with their approvals spanning obesity and type 2 diabetes, conditions whose prevalence increases substantially after menopause. MOTS-c, a mitochondria-derived peptide with AMPK-activating properties, is investigated as a more upstream metabolic regulator that may address the bioenergetic root of postmenopausal insulin resistance. SS-31 targets mitochondrial membrane integrity, potentially improving cellular energy production efficiency in metabolically stressed tissues.

Skin & Connective Tissue

Estrogen plays a significant role in maintaining dermal collagen content, and its decline during perimenopause produces an accelerated reduction in skin thickness and elasticity. GHK-Cu, a copper tripeptide naturally present in human plasma, has been investigated for its capacity to activate collagen synthesis genes and tissue remodelling pathways, research has demonstrated stimulation of collagen and glycosaminoglycan production in dermal models. BPC-157 has been studied for joint integrity, tendon and ligament healing, and connective tissue repair, areas of practical relevance to menopausal women experiencing increased joint laxity and delayed recovery.

Sleep & Circadian Regulation

Sleep disruption is among the most consistently reported symptoms of perimenopause and menopause, with contributions from vasomotor episodes, altered circadian melatonin secretion, and loss of the sleep-promoting effects of progesterone. Epitalon has been investigated for its potential to normalise age-related decline in pineal melatonin production, with research in elderly human cohorts reporting improvements in sleep quality and circadian hormone patterns. GH secretagogues, particularly Sermorelin and Ipamorelin, are associated with increased slow-wave (stage 3) sleep in research contexts, driven by the coupling between GH secretion and deep sleep architecture, a relationship that becomes relevant as both GH output and sleep quality deteriorate in parallel during the menopausal transition.

Libido & Sexual Function

Hypoactive sexual desire is reported by a significant proportion of perimenopausal and postmenopausal women, arising from a combination of hormonal, neurological, and psychological factors. PT-141 (bremelanotide) acts on MC3R and MC4R receptors in the CNS to activate arousal pathways that are partly independent of circulating hormone levels, which is mechanistically distinct from hormone replacement approaches to libido. It is FDA-approved as Vyleesi for HSDD in premenopausal women; its approval does not extend to postmenopausal HSDD. Research on PT-141 in perimenopausal women remains ongoing, and its use in this context is investigational. Kisspeptin may also have indirect relevance to sexual motivation through its hypothalamic actions, though research in this area is preliminary.

Kisspeptin

Kisspeptin is produced by hypothalamic KNDy neurons and functions as the primary upstream regulator of GnRH pulsatility. Declining estrogen during perimenopause removes the negative feedback that normally restrains these neurons, leading to hyperactivation, a mechanism proposed to underlie hot flushes via aberrant connections to the thermoregulatory centre. Clinical research has primarily investigated Kisspeptin-10 and Kisspeptin-54 for LH pulsatility restoration in hypogonadotropic hypogonadism and as oocyte maturation triggers in IVF. Applications in menopause symptom research are emerging but remain in early phases. It is not approved for any menopause indication.

Sermorelin

Sermorelin is the synthetic 1–29 N-terminal fragment of human GHRH, the minimal sequence required for GHRH receptor binding and GH secretion stimulation. It was FDA-approved as Geref for paediatric GH deficiency; its use in aging adults is off-label. Research has investigated Sermorelin for its potential role in restoring more youthful GH pulsatility in older adults, including postmenopausal women, with reported improvements in body composition, bone density, and sleep quality. Peptide menopause support protocols frequently cite Sermorelin as a first-line GH secretagogue given its long clinical research history compared to newer analogues.

Ipamorelin

Ipamorelin is a selective GHSR-1a agonist with a favourable side effect profile distinguished by its absence of cortisol and prolactin elevation, a pharmacological advantage over earlier-generation GH secretagogues such as GHRP-2 and GHRP-6. Research has investigated Ipamorelin for lean mass preservation, bone mineral density, and GH-mediated metabolic support in aging populations. Its selectivity makes it a frequently cited compound in GH peptides for women over 40 research discussions. It is commonly reported in combination with CJC-1295, where the GHRH analogue and GHSR agonist produce additive GH stimulation through complementary receptor mechanisms.

PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist with FDA approval (as Vyleesi) for HSDD in premenopausal women. Its mechanism is CNS-based: MC3R and MC4R activation in the hypothalamus and limbic system produces arousal and desire responses that are partly independent of circulating estrogen or testosterone levels. This mechanism is mechanistically distinct from hormone replacement approaches and is one reason for research interest in perimenopausal women where hormonal correction alone may not fully restore libido. The FDA approval is restricted to premenopausal women; its use in peri- or postmenopausal contexts is investigational. Reported side effects include transient flushing, nausea, and transient blood pressure elevation.

Epitalon

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal gland peptide preparation. Research from the Khavinson group has investigated Epitalon for its potential to normalise age-related decline in melatonin secretion from pineal tissue and to activate telomerase in somatic cell lines. In human cohort studies, Epitalon administration has been reported to improve sleep quality and circadian hormone patterns in elderly subjects. In the context of menopause, declining melatonin production contributes to sleep disruption and circadian dysregulation; Epitalon's pineal-targeting mechanism positions it as a relevant research subject even in the absence of estrogen-facing pharmacology.

GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide whose plasma concentration declines significantly with age. Research has demonstrated its capacity to upregulate hundreds of genes involved in tissue repair, collagen synthesis, antioxidant defence, and anti-inflammatory signalling. In dermal research contexts, GHK-Cu has been shown to stimulate collagen and glycosaminoglycan production, directly relevant to the accelerated skin collagen decline observed in perimenopause. It is available topically in cosmetic formulations and subcutaneously in research protocols. It does not address hormonal causes of skin aging but targets the cellular repair and remodelling machinery that estrogen normally supports.

BPC-157

BPC-157 is a 15-amino acid synthetic peptide derived from a gastric juice protein. Research has investigated it for tendon and ligament repair, joint health, gut mucosal protection, and systemic anti-inflammatory effects via nitric oxide pathway modulation and VEGFR2-mediated angiogenesis. Its relevance in the menopause context lies primarily in the connective tissue and joint domain: declining estrogen reduces joint lubrication and collagen density, increasing susceptibility to musculoskeletal injury and delayed recovery. BPC-157's healing-promoting mechanism addresses this tissue-level vulnerability without engaging hormonal pathways directly.

Collagen Peptides

Collagen peptides (hydrolysed collagen) are the most directly relevant oral intervention for the structural connective tissue changes associated with estrogen decline. Studies estimate up to 30% skin collagen loss in the first 5 years following menopause, driven primarily by the loss of estrogen's stimulatory effects on dermal fibroblasts. Randomised controlled trials have reported improvements in skin elasticity and hydration following 8 to 12 weeks of oral collagen peptide supplementation at 2.5 g to 10 g per day. Separately, a randomised controlled trial published in Nutrients (2018) specifically investigated specific bioactive collagen peptides in postmenopausal women over 12 months and reported significant increases in bone mineral density at the lumbar spine and femoral neck, alongside increased bone formation markers, providing clinical trial evidence directly relevant to postmenopausal bone health. Collagen peptides are classified as food supplements, widely available without prescription, and have a well-established tolerability profile across multiple clinical trials, making them pharmacologically accessible alongside other compounds in this category.

Regulatory Note

No peptide is currently FDA-approved for menopause or perimenopause symptom management. PT-141 (Vyleesi) holds approval for HSDD in premenopausal women only; this approval does not extend to postmenopausal HSDD or other menopause symptoms. Semaglutide and Tirzepatide are approved for obesity and type 2 diabetes, conditions prevalent in menopause, but not for menopause itself. All other compounds on this page are investigational in the menopause context. This page is an educational research reference and does not constitute medical advice. Any consideration of peptide use should involve a qualified clinician familiar with individual health status.

Which peptides are researched for perimenopause?

Research has investigated several peptide classes in the context of perimenopause. Kisspeptin is studied for HPG axis regulation and gonadotropin stimulation. GH secretagogues, Sermorelin, Ipamorelin, and CJC-1295, are investigated for body composition, bone density, and sleep quality. GHK-Cu is studied for skin collagen maintenance. PT-141 is researched for libido and sexual function. Epitalon is studied for circadian and sleep regulation. SS-31 and MOTS-c are investigated for mitochondrial and metabolic health. All remain investigational in the menopause context; none are approved for menopause symptom management.

Can peptides help with menopause symptoms?

No peptide is currently approved for menopause symptom management. Research suggests that several compounds may address specific biological changes associated with perimenopause, including HPG axis dysregulation, GH axis decline, insulin resistance, skin collagen loss, and sleep disruption, but controlled clinical trial data in menopausal women is limited for most of these compounds. This page provides a research reference, not medical advice. Any consideration of peptide use should involve a qualified clinician.

Is there an FDA-approved peptide for menopause?

No. PT-141 (bremelanotide, sold as Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women specifically, its approval does not extend to postmenopausal HSDD or other menopause indications. No other peptide currently holds FDA approval for any menopause indication. GLP-1 agonists such as Semaglutide and Tirzepatide are approved for obesity and type 2 diabetes, conditions whose prevalence increases after menopause, but not for menopause itself.

How does Kisspeptin relate to menopause?

Kisspeptin neurons in the hypothalamic arcuate nucleus drive GnRH pulsatility and are the primary upstream regulators of LH and FSH secretion. During perimenopause and menopause, declining estrogen removes negative feedback on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, causing their dysregulated hyperactivation. This dysregulation is believed to contribute to hot flushes and vasomotor symptoms through aberrant connections to the hypothalamic thermoregulatory centre. Research has investigated whether kisspeptin modulation could offer a targeted approach to this neurological symptom mechanism, though clinical trial data in menopausal women remains preliminary.

What peptides are studied for bone and muscle loss during menopause?

GH secretagogues are the primary peptide class investigated for bone and muscle preservation in the context of menopause-related GH axis decline. Ipamorelin has been studied for bone mineral density and lean mass. CJC-1295 augments GH pulse amplitude and sustains IGF-1 elevation. Sermorelin is the most clinically researched GHRH analogue in aging adults and has been investigated in postmenopausal women specifically. BPC-157 is studied for joint and connective tissue health. None of these compounds are approved for osteoporosis or sarcopenia in menopause; all use in this context is investigational.